DrugsData is the independent laboratory drug analysis program of Erowid Center. Launched in July 2001, its purpose is to collect, manage, review, and present laboratory drug analysis results. The information is made publicly available to help harm-reduction efforts, medical personnel, and researchers. While some government agencies analyze psychoactive drugs, they choose to restrict the data they collect and make it private to law enforcement interests.
DrugsData collects lab testing results from a variety of organizations, but primarily commissions its own tests conducted by Drug Detection Labs (DDL). All samples are submitted to DrugsData anonymously by mail. We do not accept samples submitted in person. We also help other analysis projects to publish and manage their testing data. Please read Less Ecstasy, More Data: 15 Years of the EcstasyData Program and contact us for more information.
DrugsData is a project of Erowid Center. Erowid works with the testing laboratory to process submissions and publish results, and collects data from other testing organizations (e.g. drug checking groups in Europe), develops software, fundraises, and maintains the DrugsData.org website.
Erowid invests in drug analysis / drug checking in order to increase the quality of information available about psychoactive substances. Independent laboratory drug checking is the only information currently publicly available about the variety and identity of adulterants in psychoactive drugs around the world. Erowid believes the consistent collection and publication of this information is an important part of developing a foundation for appropriate public policies and emergency medical responses. The information is useful for families, teachers, lawyers, users, news agencies, law enforcement, and any other group that needs to know what is in the ecstasy which is increasingly available throughout the world.
Isomer Design began financial support for DrugsData/EcstasyData in August 2013. Isomer Design tracks the emergence of novel psychoactive substances to help reduce harm and misinformation associated with these drugs. Isomer Design supports independent lab testing of new psychoactive substances and is helping to sponsor testing of novel psychoactive substances through DrugsData and other academic projects.
Isomer Design also supports harm-reduction and drug policy-reform organizations including the Canadian Drug Policy Coalition, Canadian Students for Sensible Drug Policy, MAPS Canada, Bluelight, and Drugs-Forum.
DrugsData tests all psychoactive drugs including ecstasy tablets, powders, research chemicals, novel pschoactive substances, and other drugs through our DEA-licensed laboratory. Ecstasy/Molly tablets cost $100. Recreational drug powder/crystal/blotter costs $100. Pharmaceuticals, supplements and all others cost $150 per analysis.Learn more
Should the public have access to independent analysis of the products they consume?
The vast majority of analyses of over-the-counter, prescription, and recreational drugs are performed in secret with no independent oversite or review. No other historical record, free from politically-controlled agencies, is currently available in North America nor most other parts of the world.
DrugsData, a project of Erowid Center, needs the support of professionals, students, parents, individuals with means, and small foundations for a total yearly budget of around $120,000 USD. Erowid Center's general budget and the co-pays we require fund most of this cost.Donate now